Zumax Medical listed on the Innovation Tier of the National Equities Exchange and Quotations (NEEQ).Issuing time:2026-10-13 15:28
DentalGoodNews｜On October 13, 2026, Suzhou Zumax Medical Technology Co., Ltd. (hereinafter referred to as "Zumax Medical") was officially listed for public transfer on the Innovation Tier of the National Equities Exchange and Quotations (hereinafter referred to as "NEEQ"), with the securities code "875259" and the trading method of call auction. According to Zumax Medical's public transfer prospectus, the company's operating revenue in 2025 was RMB 354 million, an increase of 9.34% compared with RMB 323 million in 2024; net profit attributable to owners of the parent company was RMB 56.133 million, a decrease of 7.16% compared with RMB 60.46 million in 2024.
By product, dental surgical microscopes remained the main source of revenue for Zumax Medical. In 2025, revenue from this product was RMB 267 million, accounting for 75.53% of main business revenue, an increase of 7.77% compared with RMB 248 million in 2024; the proportion decreased by 1.12 percentage points from 76.65% in 2024.
By region, in 2025, overseas sales revenue was RMB 186 million, an increase of 3.25% compared with RMB 181 million in 2024; overseas sales revenue accounted for 52.75% of operating revenue, down 3.11 percentage points from 2024; domestic sales revenue was RMB 167 million, an increase of 17.05% compared with RMB 143 million in 2024, and its proportion of operating revenue rose from 44.14% to 47.25%. In overseas markets, revenue from Europe was RMB 96.052 million, down 3.93% from 2024, with its proportion decreasing from 30.92% to 27.17%; in the domestic market, the Southwest region grew the fastest, increasing from RMB 13.5426 million to RMB 22.896 million, up 69.07%.
According to previous reports by DGN, Zumax Medical completed a Pre-IPO financing round of nearly RMB 100 million in 2022, jointly invested by Jiale Capital, Suzhou High-tech Venture Capital, and Yueyin Medical Fund, with the funds mainly used for new product development and market expansion. In addition, Zumax Medical submitted an application for listing on the ChiNext Board to the Shenzhen Stock Exchange in July 2023, planning to raise RMB 508 million for expanding production of surgical microscopes and upgrading its R&D center. However, due to factors such as changes in the IPO market environment, its ChiNext listing application was terminated in April 2024. About Zumax Medical (ZUMAX): Suzhou Zumax Medical Technology Co., Ltd., founded in Suzhou in 2005, focuses on the R&D, production, and sales of surgical microscopes. The company possesses four core technologies: medical micro-optics, precision machinery and automation, digital imaging, and surgical navigation, and has obtained multiple patent authorizations. Its products cover dental and surgical microscopes, have passed U.S. FDA and EU CE certifications, and are sold to more than 100 countries worldwide. In 2022, it was recognized as a National Specialized, Sophisticated, Unique & Novel 'Little Giant' Enterprise, and in 2024, it was recognized as a National Key Little Giant Enterprise.
【GOODNEWS】 Content for industry reference only (based on public info & professional judgment); not for decision-making. Readers bear full responsibility for their own judgment and risks.
Copyright © This Platform. Unauthorized reproduction & commercial use prohibited.
Errata, contributions & cooperation: Contact customer service via WeChat:HDSW_001
|
✉️
Subscribe to Our
Newsletter
We curate important stories and exclusive insights, delivered straight to your inbox.
In-depth analysis · Exclusive content · Fast-moving news
|
